The 'Monster' Origin Of Weight Loss Drugs Like Ozempic: WSJ

The development of blockbuster diabetes drugs like Ozempic and Mounjaro, which have revolutionized obesity treatment, can be traced back to decades-old studies of two unlikely creatures: the Anglerfish and the Gila monster, The Wall Street Journal reports.

From Anglerfish to GLP-1

In 1980, researchers at Massachusetts General Hospital studied Anglerfish to find the gene that encodes a hormone called glucagon. They discovered a related hormone, glucagon-like peptide-1 (GLP-1), which was later found to encourage insulin release, lower blood sugar, and make people feel fuller faster. However, GLP-1 disappears from the human body quickly, making it difficult to develop into a drug.

The Gila Monster’s Contribution

Meanwhile, researchers studying Gila monster venom found a peptide similar to human GLP-1. This peptide, named Exendin-4, reduced blood glucose in diabetic mice for hours, suggesting it could be developed into a diabetes treatment.

From Exendin-4 to Ozempic

Pharmaceutical company Amylin developed Exendin-4 into a drug, which was approved by the FDA in 2005. This success spurred other companies, including Novo Nordisk, to develop more effective and longer-lasting GLP-1 drugs. Novo Nordisk’s semaglutide, known by the brand names Ozempic and Wegovy, is now a blockbuster drug for weight loss and diabetes treatment.

Benzinga Newsbot

Hi, I am the Benzinga Newsbot! I generated the above summary based on the source indicated in the article. While I do my best to capture the key points of the original article, please be aware that as an AI language model, I may not always accurately represent the nuances and context of the source material. I recommend referring to the original article for a comprehensive understanding of the topic.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsHealth CareGeneralOzempicWeight Loss
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!